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Abstract: Chronic obstructive pulmonary disease (COPD), a complex progressive disease, 
is currently the third leading cause of death worldwide. One recommended treatment option 
is fixed-dose combination therapy of an inhaled corticosteroid (ICS)/long-acting β-agonist. 
Clinical trials suggest pressurized metered-dose inhalers (pMDIs) and dry powder inhalers 
(DPIs) show similar efficacy and safety profiles in COPD. Real-world observational studies 
have shown that combination therapy has significantly greater odds of achieving asthma control 
when delivered via pMDIs. Our aim was to compare effectiveness, in terms of moderate/severe 
COPD exacerbations and long-acting muscarinic antagonist (LAMA) prescriptions, for COPD 
patients initiating fluticasone propionate (FP)/salmeterol xinafoate (SAL) via pMDI versus DPI 
at two doses of FP (500 and 1,000 μg/d) using a real-life, historical matched cohort study. COPD 
patients with $2 years continuous practice data, $2 prescriptions for FP/SAL via pMDI/DPI, 
and no prescription for ICS were selected from the Optimum Patient Care Research Database. 
Patients were matched 1:1. Rate of moderate/severe COPD exacerbations and odds of LAMA 
prescription were analyzed using conditional Poisson and logistic regression, respectively. Of 
472 patients on 500 μg/d, we observed fewer moderate/severe exacerbations in patients using 
pMDI (99 [42%]) versus DPI (115 [49%]) (adjusted rate ratio: 0.71; 95% confidence interval: 
0.54, 0.93), an important result since the pMDI is not licensed for COPD in the UK, USA, or 
China. At 1,000 μg/d, we observed lower LAMA prescription for pMDI (adjusted odds ratio: 
0.71; 95% confidence interval: 0.55, 0.91), but no difference in exacerbation rates, potentially 
due to higher dose of ICS overcoming low lung delivery from the DPI.
Keywords: COPD, inhaler type, exacerbations, pneumonia, diabetes, dose-response, inhaled 
steroid/LABA combination
Introduction
Therapies for chronic obstructive pulmonary disease (COPD) aim at improving 
symptom control and reducing exacerbations.1 The two most commonly used devices 
in clinical practice to achieve effective treatment delivery to the lungs are pressur-
ized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). The correct use 
of these devices requires precision, and different devices require specific inhalation 
techniques. It is therefore not surprising that errors in inhalation2 are common among 
patients using either pMDI3 and/or DPI4–6 devices.
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A currently recommended, and widely employed, 
therapy option for patients with COPD is fixed-dose com-
bination therapy with a long-acting β-agonist (LABA) and 
an inhaled corticosteroid (ICS).1 Combination therapy was 
found to be more convenient than individual treatments, as 
well as improving lung function and reducing exacerbations 
in patients with moderate to severe COPD.1,7 Several ICS/
LABA combination products are available that differ in 
pharmacokinetic profile and dose of both active substances.8 
Fluticasone propionate/salmeterol xinafoate (FP/SAL) is 
an ICS/LABA fixed-dose combination therapy that can be 
delivered either by pMDI or DPI. In the UK and People’s 
Republic of China, twice-daily FP/SAL 500 μg fluticasone 
propionate and 50 μg salmeterol (1,000 μg/d) is licensed for 
the treatment of COPD as a DPI, but not as a pMDI.9–11 The 
licensed dose in the USA is 250/50 μg twice daily, again 
via DPI (500 μg/d).11 Nonetheless, FP/SAL prescription in 
unlicensed devices and doses is common worldwide.12–15
The effects of both salmeterol and fluticasone mono-
therapies in COPD have been widely studied. Most of these 
studies assessed delivery of these therapies via pMDI. 
Salmeterol was found to be superior to placebo for relief 
of dyspnea.16,17 The Inhaled Steroids in Obstructive Lung 
Disease in Europe (ISOLDE) trial found that treatment 
with FP pMDI in COPD patients decreased exacerbation 
frequency and severity compared to placebo.18 The treat-
ment of COPD with FP/SAL DPI was found to have a 
greater improvement on forced expiratory volume than the 
individual therapies.19 Although DPI is extensively used for 
the treatment of COPD, there are occasions when an MDI 
is the preferred treatment by the patient or due to clinical 
circumstances, such as intubation. A clinical trial by Koser 
et al20 compared the effect of FP/SAL combination therapy 
delivered by DPI or MDI and found that efficacy and safety 
profile in COPD patients were comparable for both devices. 
However, the stringent patient selection of randomized con-
trolled trials (RCTs) makes them less representative of the 
real-life COPD patient population. Our previous real-world 
observational studies have shown that patients with asthma 
treated with FP/SAL pMDI therapy have significantly greater 
odds of achieving asthma control than those treated with 
FP/SAL via DPI.21 Given the abovementioned differences 
between the two devices and the observational studies in 
asthma patients, it is possible there may also be differences 
in the effectiveness of these two devices in the real-world 
treatment of COPD. The use of nationwide databases to 
conduct real-life studies allows us to examine longer term 
outcomes, providing information to complement the results 
of RCTs. Observational studies allow the assessment of 
patients normally excluded from RCTs, such as those with 
variable ability to use inhalers, often excluded from RCTs 
as it is considered unethical to prescribe inhalers to people 
who cannot use them. A broader patient population with a 
greater age range, compared to that in RCTs, is available to 
study. These studies also make it possible to more closely 
examine the effects of the normal ecology of care with less 
follow-up and retraining in using devices. Real-world obser-
vational studies cast a wider investigation net through the 
consideration of unselected, representative patients managed 
in real-life clinical practice.22,23
The aim of this study was to compare the effectiveness 
and safety of initiating FP/SAL using pMDI versus DPI at 
two doses (500 and 1,000 μg/d) for patients with COPD, 
using a matched, historical cohort study in the UK.
Materials and methods
Study design
This was an exploratory historical, matched cohort study 
comparing patients initiating with FP/SAL via pMDI 
(investigational therapy) to those initiated via DPI (reference 
therapy). We examined data during a one-year baseline 
period (prior to the index date, defined below) for patient 
characterization, and a one-year outcome period after initia-
tion of FP/SAL therapy. The index date was defined as the 
date of first prescription for FP/SAL via either pMDI or DPI 
for each initiation dose of FP/SAL (500 μg/d or 1,000 μg/d). 
This study design was used to determine the rate of moderate/
severe COPD exacerbations and the odds of receiving a 
long-acting muscarinic antagonist (LAMA) prescription, and 
diagnosis of pneumonia and type 2 diabetes mellitus, during 
the outcome period, for pMDI versus DPI.
ethical approval
The study was designed, implemented, and reported in 
accordance with the criteria of the European Network Cen-
tres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP; registration number ENCEPP/SDPP/7072) and 
followed the ENCePP code of conduct. This study was 
conducted to standards recommended for observational 
research23 and was approved by the Anonymized Data Eth-
ics Protocols and Transparency committee (ADEPT) – the 
independent scientific advisory committee for the Optimum 
Patient Care Research Database (OPCRD); patient consent 
was not required due to the retrospective nature of this 
study, as approved by this committee (Approval Reference 
ADEPT0417).
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Data source
The study utilized data from the OPCRD.22 The OPCRD is 
a bespoke database that, at the time of this study, contained 
anonymous longitudinal data for over 2.8 million patients 
from over 500 general practices across England, Scotland, 
Wales, and Northern Ireland. It contains two types of data: 
1) routinely recorded clinical data and 2) questionnaire 
responses from over 40,000 patients with respiratory condi-
tions. The database has been approved by the Trent Multi 
Centre Research Ethics Committee for clinical research 
use. The data include routinely collected information on 
diagnosis, prescriptions, investigations, hospital referrals, 
and admissions.
Patient population
Patients eligible for the study were $35 years of age at the 
time of first prescription of FP/SAL, had a coded diagnosis 
of COPD, forced expiratory volume in 1 second/forced vital 
capacity ratio ,0.7, $2 prescriptions for FP/SAL via pMDI/
DPI, and at least 2 years of continuous practice data compris-
ing 1 baseline year and 1 outcome year. Patients were excluded 
from the analysis if their records contained diagnostic codes 
for any chronic respiratory illness other than COPD, asthma, 
or bronchiectasis. Patients prescribed maintenance oral ste-
roids were excluded, as were patients with $1 prescription 
for ICS, including as part of a fixed-dose combination, during 
the baseline period. Patients with a diagnostic read code for 
pneumonia during the baseline period were also excluded. 
Number of patients excluded are shown in Figure S1.
sample size
29,381 patients in the OPCRD were prescribed ICS/LABA 
combination therapy via either pMDI or DPI at the index 
date. Of these, 5,298 met the inclusion criteria. Combina-
tion FP/SAL (Seretide®, Glaxo Group Limited, London, 
UK) was administered via DPI (Accuhaler® Diskus®, 
Glaxo Group Limited) or pMDI (Evohaler®, Glaxo Group 
Limited) device. Patients were matched 1:1, resulting in a 
total of 1,684 uniquely matched patients who initiated at 
the same dose of FP/SAL (ie, 842 patients using pMDI and 
842 using DPI; Table 1, Figure S1). Analyses were carried 
out within cohorts determined by initial dose: 236 matched 
pairs were included in the “500 μg/d cohort” (actual dose 
ranged from 400–500 μg/d), and 586 matched pairs were 
included in the “1,000 μg/d cohort” (actual dose ranged 
from 1,000 to 2,000 μg/d; Figure S1). Patients initiating on 
250 μg/d were not analyzed as there were too few to conduct 
an analysis (n=40).
exact matching
We used exact matching with statistical adjustment for base-
line values for outcomes of interest, as described in previous 
studies,24,25 to ensure that we analyzed comparable groups 
of patients. We compiled a list of potential matching criteria 
informed by expert clinical advice and previous research expe-
rience, including variables predictive of outcomes and the key 
baseline clinical characteristics differing between unmatched 
cohorts (identified using t-test, χ2 or Mann–Whitney U-tests, as 
appropriate). The matching process was carried out in two steps. 
First, potential matches were selected for a patient based on the 
matching criteria described in Table 1. Second, that patient was 
matched to one of the potential matches who were initiated on 
the same dose of FP/SAL. This produced two matched cohorts 
containing all possible pairings; bespoke software was used to 
randomly select final unique matched pairs.
Study outcomes
The primary study end point was the number of moderate/
severe COPD exacerbations in the outcome period in patients 
prescribed FP/SAL via pMDI versus DPI at 500 μg/d and 
1,000 μg/d. These were defined as per American Thoracic 
Society/European Respiratory Society criteria as a COPD-
related hospitalization (emergency department attendance 
or inpatient admittance) or acute course of oral corticoster-
oids associated with a lower respiratory consultation. The 
secondary end points were the odds of any LAMA pre-
scriptions, pneumonia, and onset of type 2 diabetes mellitus 
between the devices at 500 μg/d. Onset of type 2 diabetes 
was determined for patients without diabetes mellitus prior 
to first prescription of FP/SAL.
Statistical analysis
Statistical analysis was carried out using SPSS Statistics version 
22 (IBM SPSS Statistics, Feltham, Middlesex, UK) and SAS 
version 9.3 (SAS Institute, Marlow, Buckinghamshire, UK).
Table 1 selected matching criteria
Criteria Categories 
sex Male/female
Age at initiation with FP/SAL ±5 years
Baseline COPD exacerbations 0, 1, 2, 3+
Number of baseline LAMA 
prescriptions
0, 1, 2+
Baseline lower respiratory 
tract infections
0, 1, 2, 3+
Diabetes diagnosis at or prior 
to initiation with FP/SAL
Diabetes with no insulin/diabetes 
and insulin/no diabetes
Abbreviations: COPD, chronic obstructive pulmonary disease; FP/SAL, fluticasone 
propionate/salmeterol xinafoate; LAMA, long-acting muscarinic agonist.
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This was an exploratory study; therefore, no formal 
sample size calculation was performed. The sample size was 
based on practicality and resource constraints.
The rate of moderate/severe COPD exacerbations was 
analyzed using Poisson regression. The proportion of LAMA 
prescription and onset of type 2 diabetes and pneumonia were 
analyzed using conditional logistic regression.
The models were adjusted for respective baseline values 
of the outcome variable of interest where possible.
No sensitivity analysis was planned for this exploratory 
study.
Results
Study population
We studied 236 matched pairs in the 500 μg/d cohort and 
586 matched pairs in the 1,000 μg/d cohort. Baseline patient 
characteristics of the pMDI and DPI arms within each dose 
cohort after matching were generally similar (Table 2). 
Patient compliance above 80%, based on prescription refills, 
was similar for both pMDIs (53.4%) and DPIs (49.5%). 
Smoking status was not significantly different within the two 
cohorts (Table 2). However, in the 500 μg/d cohort, the pMDI 
arm had fewer patients with chronic kidney disease compared 
to those in the DPI arm with the same dose (Table 2).
Outcomes
In the 500 μg/d cohort, there were less moderate/severe 
COPD exacerbations over the outcome period for patients 
prescribed pMDI compared with those prescribed DPI, after 
adjustment for baseline exacerbations (rate ratio: 0.71, 95% 
confidence interval [CI]: 0.54, 0.93) (Table 3, Figure 1). 
A total of 42% of patients experienced exacerbations when 
taking 500 μg/d of FP/SAL via pMDI compared to 49% of 
those using DPI with the same dose (P=0.032). The most 
evident difference was seen in patients experiencing $4 
exacerbations during the outcome year (8 [3%] in those using 
pMDI versus 21 [9%] using DPI) (Table 3). There were no 
significant differences observed in LAMA prescriptions 
after adjustment for baseline LAMA prescription (odds 
ratio [OR]: 0.79, 95% CI: 0.49, 1.26). The incidence of 
pneumonia and type 2 diabetes was not significantly differ-
ent between patients using the different inhalers (unadjusted 
ORs: 1.25, 95% CI: 0.33, 4.76, and 1.35, 95% CI: 0.45, 4.03, 
respectively).
Table 2 Baseline patient characteristics
Characteristic FP/SAL 500 µg/d FP/SAL 1,000 µg/d
pMDI
(n=236) 
DPI
(n=236)
P-valuea pMDI
(n=586)
DPI
(n=586)
P-valuea
sexb, n (%) male 136 (58) 136 (58) N/A 355 (61) 355 (61) N/A
ageb (years), median (IQR) 68 (61, 75) 67 (61, 75) 0.319 69 (62, 75) 69 (63, 75) 0.959
Year of first prescription of 
FP/SAL, median (IQR)
2006
(2004, 2008)
2006
(2004, 2008)
0.013 2007
(2005, 2009)
2009
(2006, 2010)
,0.001
smoking status, n (%)
non 29 (12) 34 (14) 0.238 40 (7) 42 (7) 0.940
Current 104 (44) 87 (37) 252 (43) 251 (43)
ex 102 (43) 115 (49) 293 (50) 292 (50)
gOlD group,c n (%)
a 65 (33) 72 (37) 0.915 141 (29) 147 (28) 0.901
B 48 (25) 46 (24) 118 (24) 123 (23)
C 39 (20) 42 (21) 114 (23) 113 (22)
D 43 (22) 36 (18) 119 (24) 143 (27)
Moderate/severe COPD  
exacerbations,b n (%)
0 123 (52) 129 (55) 0.368 299 (51) 302 (52) 0.207
1 62 (26) 60 (25) 174 (30) 164 (28)
2–3 48 (20) 41 (17) 91 (16) 100 (17)
$4 3 (1) 6 (3) 22 (4) 20 (3)
laMa prescription,b n (%) 17 (7) 17 (7) N/A 151 (26) 151 (26) N/A
Diabetes mellitus,b,d n (%) 35 (15) 35 (15) N/A 115 (20) 115 (20) N/A
asthma,d n (%) 30 (13) 44 (19) 0.069 50 (9) 61 (10) 0.265
Ischemic heart disease,d n (%) 46 (20) 44 (19) 0.811 136 (23) 111 (19) 0.077
Chronic kidney disease,d n (%) 7 (3) 19 (8) 0.024 30 (5) 39 (7) 0.251
Notes: aConditional logistic regression; bMatching criteria; creference 52; dIdentified by diagnostic read codes recorded at or prior to initiation with FP/SAL, diabetes mellitus 
includes antidiabetic drug prescriptions, asthma excludes resolved cases, chronic kidney disease includes patients in stages 3–5 and all those with evidence of proteinuria.
Abbreviations: COPD, chronic obstructive pulmonary disease; DPI, dry powdered inhaler; FP/SAL, fluticasone propionate/salmeterol xinafoate; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease; IQR, interquartile range; LAMA, long-acting muscarinic agonist; N/A, not applicable; pMDI, pressurized metered-dose inhaler.
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In the 1,000 μg/d cohort, patients prescribed pMDI had 
fewer LAMA prescriptions in the outcome year compared to 
those on DPI (252 [43%] pMDI versus 291 [50%]) (Table 3). 
After adjustment for baseline LAMA prescriptions, the OR 
was 0.71 with 95% CI: 0.55, 0.91 (Figure 2). However, 
there was no difference observed in exacerbation rates in 
this dose cohort (rate ratio: 1.11, 95% CI: 0.94, 1.30). We 
did not observe any difference in the odds of pneumonia or 
type 2 diabetes by inhaler type in this cohort (OR: 1.33, 95% 
CI: 0.30, 5.88, and 1.04, 95% CI: 0.59, 1.82, respectively) 
(Figure 2).
Discussion
In this exploratory, real-world observational study, we found 
that the proportion of patients experiencing exacerbations in 
the 500 μg/d FP/SAL cohort was lower in those prescribed 
unlicensed pMDIs compared to those prescribed DPIs. 
This was not observed in the 1,000 μg/d FP/SAL cohort, 
where there was no significant difference in exacerbations 
in patients prescribed different inhaler devices. However, 
patients prescribed a pMDI at 1,000 μg/d had fewer LAMA 
prescriptions during the outcome period than those prescribed 
the same dose via a DPI.
Exacerbations contribute massively to the morbidity, 
mortality, and cost burden of COPD; therefore, the primary 
goals of COPD treatment are to improve symptoms and 
reduce the frequency of exacerbations.1 The GOLD guide-
lines suggest treatment escalation to ease the burden of 
disease.1 However, licensed treatments differ between 
continents, making it difficult to standardize therapy. In 
Europe, FP/SAL is licensed at 500/50 μg twice daily and is 
used in patients with milder COPD whereas, in the USA, 
it is licensed at 250/50 μg twice daily.26 Both the TORCH 
and INSPIRE studies found a reduction in moderate/severe 
exacerbations in patients prescribed 1,000 μg/d FP/SAL 
compared to monotherapy FP or SAL and placebo.27,28 
Table 3 Moderate/severe COPD, LAMA prescription, pneumonia, and diabetes mellitus during the outcome year
Characteristic FP/SAL 500 µg/d FP/SAL 1,000 µg/d 
pMDI
(N=236) 
DPI
(N=236)
P-value 
(CLR)
pMDI
(N=586)
DPI
(N=586)
P-value 
(CLR)
Moderate/severe COPD  
exacerbations, n (%)
0 137 (58) 121 (51) 299 (51) 317 (54)
1 56 (24) 59 (25) 0.032 152 (26) 149 (25) 0.245
2–3 35 (15) 35 (15) 100 (17) 87 (15)
$4 8 (3) 21 (9) 35 (6) 33 (6)
laMa prescription, n (%) 51 (22) 59 (25) 0.319 252 (43) 291 (50) 0.008
Pneumonia, n (%) 5 (2) 4 (2) 0.739 4 (1) 3 (1) 0.706
Diabetes mellitus,a n (%) 8 (4) 6 (3) 0.594 27 (6) 26 (6) 0.889
Note: aAs a percentage of patients without diabetes mellitus prior to first prescription of FP/SAL.
Abbreviations: CLR, conditional logistic regression; COPD, chronic obstructive pulmonary disease; DPI, dry powdered inhaler; FP/SAL, fluticasone propionate/salmeterol 
xinafoate; LAMA, long-acting muscarinic agonist; pMDI, pressurized metered-dose inhaler.
??????
??????????????????????
??????????????????????????????????
?????????????????
?????????
?????????????????
??????????????
??? ? ? ? ?
???????????????
??????????????????
??????????????????
??????????????????
??????????????????
Figure 1 Comparison of outcomes between pMDI and DPI, in the 500 μg/d cohort.
Notes: *RR adjusted for number of baseline moderate/severe COPD exacerbations; †OR adjusted for baseline LAMA prescription (yes/no); ‡unadjusted Or.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; LAMA, long-acting muscarinic agonists; MDI, metered-dose 
inhaler; OR, odds ratio; pMDI, pressurized metered-dose inhaler; RR, rate ratio.
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However, lower doses of FP/SAL have also been shown 
to significantly decrease exacerbations.29,30 In the current 
study, the lower dose is where we observed a difference in 
outcomes depending on inhaler device used. Specifically, we 
observed a decrease in exacerbations in patients prescribed 
500 μg/d FP/SAL via pMDI (an unlicensed inhaler in the 
UK), compared to those prescribed the same dose via a 
licensed DPI.
Despite FP/SAL pMDI not being licensed for treatment 
of COPD,9,10 off-label prescription of FP/SAL is common. 
The choice of inhaler prescribed by a physician depends on 
multiple factors, including size of the inhaler, patient age, 
ability to correctly handle the device, presence of comorbidi-
ties, and patient preference. For example, with the standard 
pMDI inhaler, there are certain groups of patients that have 
a higher risk of poor inhalation technique including extreme 
ages, ie, very young children and the elderly, patients 
with motor impairment of upper extremities, and those with 
comorbidities such as stroke. Furthermore, patients with 
more advanced disease will have more pulmonary obstruction 
and therefore may find it difficult to inhale forcefully. These 
patients may not be able to efficiently use inhalers, such as 
DPIs, that require a deep and forceful inhalation.31 This is 
supported by a study in 26 elderly COPD patients that showed 
that the ability to generate sufficient inspiratory flow through 
a DPI is compromised.32 Using peak inspiratory flow (PIF) 
as a proxy marker of inspiratory muscle strength,33 COPD 
patients with inadequate inspiratory flow through a DPI, who 
are using DPIs as maintenance treatment, are potentially at 
risk of suboptimal drug delivery to the lungs. A US study of 
179 patients with COPD with airflow obstruction found that 
48% had suboptimal PIF rates for their DPI device. In the 
inadequate PIF cohort (PIF ,60 L/min), there were fewer 
days to COPD-related or all-cause readmission, compared 
with patients with adequate PIF.34
An investigation into serious inhaler errors, using a DPI 
for asthma control, found that over 50% of patients studied 
made between 1 and 10 serious errors. One of the most 
frequent errors recorded was inadequate inhalation effort,5 
a likely problem also for patients with COPD. Molimard 
et al35 recently found that similar device-handling errors 
frequently occur in patients with COPD, and these are 
associated with severe exacerbations.35 Inhaler misuse is 
associated with reduced adherence and has been linked to 
poor control and outcomes.3–6,36 A recent observational study 
found that reduced patient adherence may be a result of 
patients having multiple devices that require mixed inhala-
tion technique.37 The authors found that patients who used 
multiple devices with similar inhalation techniques had a 
lower exacerbation rate compared to those who used devices 
requiring mixed inhalation techniques. The prescription 
of specific inhaler devices requires clinicians to consider 
multiple factors, including the patient’s ability to handle the 
device correctly.
COPD is a heterogeneous disease with clinically relevant 
phenotypes that should be taken into consideration upon pre-
scription of therapy. Prescription of mixed inhaler regimes, 
such as DPIs for maintenance and pMDI for reliever therapy, 
are liable to confuse patients due to the very different inha-
lation techniques needed to use them correctly.37 If patients 
are unable to correctly use the inhaler prescribed, this may 
result in a decreased dose of ICS reaching the target airways 
????
??????????????????????????????????
?????????????????
?????????
????????????????? ??????????????????
??????????????????
??????????????????
??????????????????
??????????????
??????????????????????
??????
???????????????
? ? ?
Figure 2 Comparison of outcomes between pMDI and DPI, in the 1,000 μg/d cohort.
Notes: *RR adjusted for number of baseline moderate/severe COPD exacerbations; †OR adjusted for baseline LAMA prescription (yes/no); ‡unadjusted Or.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; LAMA, long-acting muscarinic agonists; MDI, metered-dose 
inhaler; OR, odds ratio; pMDI, pressurized metered-dose inhaler; RR, rate ratio.
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and not producing the desired effect on exacerbation control. 
This study did not account for mixed devices, which could 
also have had an impact on the results. Another important 
factor to consider in inhaler selection is the proportion of fine 
drug particles dispensed. The amount of ICS that reaches 
the small peripheral airways is partly dependent on particle 
size. A study by Postma et al38 found that fine-particle ICS, 
at significantly lower doses, had equivalent effects of large 
particle ICS at higher doses. The odds of achieving treatment 
success were also increased with the use of fine-particle 
ICS, and the authors suggested that this was due to greater 
lung deposition, especially to the small airways.38 pMDIs 
were found to contain a high dose of fine particles,39 which 
could explain why, at the lower dose, patients on FP/SAL 
pMDI had fewer exacerbations than patients on DPIs, and 
patients prescribed the higher dose needed fewer LAMA 
prescriptions.
Although pMDIs can be prescribed with spacers to mini-
mize the effects of incorrect inhaler use and increase lung 
deposition,40 we did not investigate whether their prescription 
had an effect on the outcome. However, a recent real-world 
study found that spacers were not associated with improved 
asthma outcomes.41
A potential weakness of DPIs is the sensitivity to humid-
ity during storage, which could be a contributing factor to 
the observed positive effect of pMDIs on exacerbations. 
Previous studies have shown, when stored in a hot and humid 
place, that there is a 50% decrease is fine particle dose with 
no significant change in delivered dose when using DPIs.42 
This could explain why we did not observe any significant 
effect on exacerbations in patients at either dose when 
delivered via DPI.
There is increasing evidence to suggest a link between 
prescription of high doses of ICS and the risk of comorbidi-
ties such as osteoporosis, diabetes, and pneumonia.43–45 This 
study did not find any significant difference in the incidence 
of pneumonia or diabetes in patients using a pMDI or a DPI 
at either dose. A recent meta-analysis of RCTs reported an 
increase in the risk of pneumonia adverse events associated 
with ICS use.46 This was more obvious at high doses of 
ICS for shorter periods of time.46,47 Both the TORCH and 
INSPIRE studies reported increased risk of pneumonia in 
patients prescribed 1,000 μg/d ICS.28,48 However, lower doses 
of ICS have also been associated with higher incidence of 
pneumonia.29,30 Our study found that the rate of pneumonia 
was low with both device types and at both doses compared 
to previous reports.49–51 Our earlier studies demonstrated 
a negative effect of ICS on patients with both COPD and 
type 2 diabetes. This negative effect was more prominent 
in patients prescribed the higher doses compared to those 
prescribed lower doses.44 However, patients who had baseline 
pneumonia and diagnosis of diabetes were excluded from 
this study. Due to the exploratory nature of this study, we 
were not able to come to a concrete conclusion with regard 
to incidence of pneumonia and/or diabetes.
The use of a large database enabled the study of real-
world outcomes with COPD inhaler devices in a repre-
sentative UK primary care population. The OPCRD is 
a high-quality data source that is well described and has 
previously been used in respiratory research.22 Although 
the OPCRD is a well-maintained and validated database, 
we cannot rule out the possibility of inaccurate or missing 
data. The outcomes were studied over a full year to balance 
seasonal influences on outcome measures. A limitation inher-
ent to observational studies is the possibility of unrecognized 
confounding factors or influences in prescribing that were 
not accounted for, eg, inhaler technique. This study, as with 
most retrospective studies, is susceptible to bias. Moreover, 
the analyses were based on recorded prescriptions for FP/
SAL; we cannot be certain that medications were dispensed 
or taken as prescribed. Finally, only one type of DPI and one 
type of pMDI were evaluated in this study; thus, our find-
ings apply to the DPI-Diskus® (Glaxo Group Limited) and 
the pMDI-Evohaler® (Glaxo Group Limited) and may not 
be applicable to other pMDI and DPI devices.
This exploratory study raises some important questions 
such as why there are not more options of inhalers licensed 
for the treatment of COPD and whether patients with dif-
ferent disease severities could benefit from changing the 
inhaler type. Further studies are necessary to confirm the 
findings of the current study. However, having a range of 
therapeutic options for the treatment of COPD that meet the 
needs of patients with different symptoms and comorbidities 
would greatly improve quality of life and minimize deleteri-
ous effects.
Conclusion
Our results suggest that FP/SAL at the unlicensed dose 
of 500 μg/d administered via pMDI is more effective at 
reducing exacerbations of COPD than the same dose admin-
istered via DPI, without any increased risk for the onset of 
pneumonia or diabetes. There is a need for international 
standardization of recommended doses and devices for 
inhaled maintenance therapies for COPD, to ensure that 
prescribers and patients have the best evidence to inform 
their treatment decisions.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
14
 o
n 
18
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2452
Jones et al
Acknowledgments
The study was funded with institutional support from 
Mundipharma International Limited. Study design, analysis, 
and data interpretation were reviewed independently by all 
authors.
Disclosure
RJ has received personal fees from Almirall, AstraZeneca, 
Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer, 
and Nutricia; grants, personal fees, and nonfinancial sup-
port from Novartis and Astra Zeneca; and personal fees and 
nonfinancial support from Mundipharma. J Martin is a former 
employee of Observational & Pragmatic Research Institute. 
VT is an employee of Cambridge Research Support. DS is 
an employee of Optimum Patient Care (OPC). J Marshall is 
an employee of Mundipharma International Limited. MSDA 
is an employee of the Observational & Pragmatic Research 
Institute (OPRI). Observational and Pragmatic Research 
Institute Pte Ltd conducted this study, with institutional sup-
port from Mundipharma and has conducted paid research in 
respiratory disease on behalf of the following organizations: 
UK National Health Service, British Lung Foundation, Aero-
crine, AKL Research and Development Ltd, AstraZeneca, 
Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, 
Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, 
Teva Pharmaceuticals, Theravance, and Zentiva. DP has 
board membership with Aerocrine, Amgen, AstraZeneca, 
Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, 
Novartis, and Teva Pharmaceuticals; consultancy agreements 
with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, 
Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, 
Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; 
grants and unrestricted funding for investigator-initiated 
studies (conducted through Observational and Pragmatic 
Research Institute Pte Ltd) from Aerocrine, AKL Research 
and Development Ltd, AstraZeneca, Boehringer Ingelheim, 
British Lung Foundation, Chiesi, Mylan, Mundipharma, 
Napp, Novartis, Pfizer, Respiratory Effectiveness Group, 
Teva Pharmaceuticals, Theravance, UK National Health 
Service, Zentiva; payment for lectures/speaking engage-
ments from Almirall, AstraZeneca, Boehringer Ingelheim, 
Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, 
Mundipharma, Novartis, Pfizer, Skyepharma, and Teva 
Pharmaceuticals; payment for manuscript preparation from 
Mundipharma and Teva Pharmaceuticals; payment for the 
development of educational materials from Mundipharma 
and Novartis; payment for travel/accommodation/meet-
ing expenses from Aerocrine, AstraZeneca, Boehringer 
Ingelheim, Mundipharma, Napp, Novartis, and Teva Phar-
maceuticals; funding for patient enrollment or completion 
of research from Chiesi, Novartis, Teva Pharmaceuticals, 
and Zentiva; stock/stock options from AKL Research and 
Development Ltd which produces phytopharmaceuticals; 
owns 74% of the social enterprise Optimum Patient Care Ltd 
(Australia, Singapore, and UK) and 74% of Observational 
and Pragmatic Research Institute Pte Ltd (Singapore); and 
is peer reviewer for grant committees of the Efficacy and 
Mechanism Evaluation program, and Health Technology 
Assessment. Seretide®, Accuhaler®, Diskus®, and Evohaler® 
are registered trademarks of Glaxo Group Limited. The 
authors report no other conflicts of interest in this work.
References
 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
[homepage]; 2017. Available from http://goldcopd.org/. Accessed 
January 10, 2017.
 2. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev. 
2005;14(96):102–108.
 3. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assess-
ment of use and patient preference of seven inhalation devices. EDICI. 
Respir Med. 2000;94(5):496–500.
 4. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry 
powder inhalers on management of patients with asthma and COPD. 
Respir Med. 2008;102(4):593–604.
 5. Westerik JA, Carter V, Chrystyn H, et al. Characteristics of patients 
making serious inhaler errors with a dry powder inhaler and association 
with asthma-related events in a primary care setting. J Asthma. 2016; 
53(3):321–329.
 6. Chrystyn H, Price DB, Molimard M, et al. Comparison of serious inhaler 
technique errors made by device-naive patients using three different 
dry powder inhalers: a randomised, crossover, open-label study. BMC 
Pulm Med. 2016;16:12.
 7. Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines 
for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637.
 8. Latorre M, Novelli F, Vagaggini B, et al. Differences in the efficacy and 
safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists 
(LABA) combinations in the treatment of chronic obstructive pulmonary 
disease (COPD): role of ICS. Pulm Pharmacol Ther. 2015;30:44–50.
 9. Accuhaler® S. Seretide DPI Summary of Product Characteristics; 2015. 
Available from https://www.medicines.org.uk/emc/medicine/2317. 
Accessed November 22, 2016.
 10. Evohaler® S. Seretide MDI Summary of Product Characteristics; 2015. 
Available from https://www.medicines.org.uk/emc/medicine/2914. 
Accessed November 22, 2016.
 11. Gao J, Pleasants RA. Role of the fixed combination of fluticasone and 
salmeterol in adult Chinese patients with asthma and COPD. Int J Chron 
Obstruct Pulmon Dis. 2015;10:775–789.
 12. Brennan PO. Inhaled salbutamol: a new form of drug abuse? Lancet. 
1983;2(8357):1030–1031.
 13. Edwards JG, Holgate ST. Dependency upon salbutamol inhalers. Br J 
Psychiatry. 1979;134:624–626.
 14. Pratt HF. Abuse of salbutamol inhalers in young people. Clin Allergy. 
1982;12(2):203–209.
 15. Thompson PJ, Dhillon P, Cole P. Addiction to aerosol treatment: the 
asthmatic alternative to glue sniffing. Br Med J (Clin Res Ed). 1983; 
287(6404):1515–1516.
 16. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. 
An evaluation of salmeterol in the treatment of chronic obstructive 
pulmonary disease (COPD). Eur Respir J. 1997;10(4):815–821.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
14
 o
n 
18
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2453
Effectiveness of initiating FP/SAL combination therapy via pMDI vs DPI
 17. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with 
salmeterol. Am J Respir Crit Care Med. 1997;155(4):1283–1289.
 18. Burge PS. EUROSCOP, ISOLDE and the Copenhagen city lung study. 
Thorax. 1999;54(4):287–288.
 19. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of 
fluticasone propionate (250 microg)/salmeterol (50 microg) combined 
in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3): 
834–843.
 20. Koser A, Westerman J, Sharma S, Emmett A, Crater GD. Safety and 
efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a 
metered-dose-inhaler compared with fluticasone propionate/salmeterol 
diskus in patients with chronic obstructive pulmonary disease. Open 
Respir Med J. 2010;4:86–91.
 21. Price D, Roche N, Christian Virchow J, et al. Device type and real-world 
effectiveness of asthma combination therapy: an observational study. 
Respir Med. 2011;105(10):1457–1466.
 22. OPCRD. The Optimum Patient Care Research Database (OPCRD); 
2016. Available from http://optimumpatientcare.org/opcrd/. 
Accessed 2016.
 23. Roche N, Reddel H, Martin R, et al. Quality standards for real-world 
research. Focus on observational database studies of comparative 
effectiveness. Ann Am Thorac Soc. 2014;11(Suppl 2):S99–S104.
 24. Stuart EA. Matching methods for causal inference: a review and a look 
forward. Stat Sci. 2010;25(1):1–21.
 25. van Aalderen WM, Grigg J, Guilbert TW, et al. Small-particle inhaled 
corticosteroid as first-line or step-up controller therapy in childhood 
asthma. J Allergy Clin Immunol Pract. 2015;3(5):721–731.e16.
 26. GSK. ADVAIR DISKUS® 250/20; 2017. Available from https://www.
gsksource.com/advair_diskus. Accessed January 19, 2017.
 27. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and 
fluticasone in the treatment of chronic obstructive pulmonary disease: 
a randomized controlled trial. Lancet. 2003;361(9356):449–456.
 28. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumo-
nia in patients with COPD: findings from the INSPIRE study. Chest. 
2011;139(3):505–512.
 29. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone 
propionate/salmeterol (250/50) on COPD exacerbations and impact 
on patient outcomes. COPD. 2009;6(5):320–329.
 30. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. 
Effect of fluticasone propionate/salmeterol (250/50 microg) or salme-
terol (50 microg) on COPD exacerbations. Respir Med. 2008;102(8): 
1099–1108.
 31. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. 
Choosing inhaler devices for people with asthma: current knowl-
edge and outstanding research needs. Respir Med. 2010;104(9): 
1237–1245.
 32. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates 
at different levels of resistance in elderly COPD patients. Eur Respir J. 
2008;31(1):78–83.
 33. Chen R, Chen R, Chen X, Chen L. Effect of endurance training on 
expiratory flow limitation and dynamic hyperinflation in patients with 
stable chronic obstructive pulmonary disease. Intern Med J. 2014; 
44(8):791–800.
 34. Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow 
rates are associated with chronic obstructive pulmonary disease and all 
cause readmissions. Ann Am Thorac Soc. 2017.
 35. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pul-
monary disease exacerbation and inhaler device handling: real-life 
assessment of 2935 patients. Eur Respir J. 2017;49(2):pii 1601794.
 36. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feas-
ability and acceptability of training by pharmacists. Respir Med. 2011; 
105(12):1815–1822.
 37. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of mul-
tiple respiratory inhalers requiring different inhalation techniques has 
an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon 
Dis. 2017;12:59–71.
 38. Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of 
small-particle versus large-particle inhaled corticosteroid in COPD. 
Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186.
 39. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons 
of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 
2002;165(10):1377–1383.
 40. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and 
outcomes of aerosol therapy: Evidence-based guidelines: American 
College of Chest Physicians/American College of Asthma, Allergy, 
and Immunology. Chest. 2005;127(1):335–371.
 41. Guilbert TW, Colice G, Grigg J, et al. Real-Life outcomes for 
patients with asthma prescribed spacers for use with either extrafine- 
or fine-particle inhaled corticosteroids. J Allergy Clin Immunol 
Pract. 2017.
 42. Borgstrom L, Asking L, Lipniunas P. An in vivo and in vitro compari-
son of two powder inhalers following storage at hot/humid conditions. 
J Aerosol Med. 2005;18(3):304–310.
 43. National Institute for Health and Care Excellence (NICE). Chronic 
obstructive pulmonary disease. Available from: https://www.nice.org.
uk/guidance/conditions-and-diseases/respiratory-conditions/chronic-
obstructive-pulmonary-disease. Accessed July 18, 2017.
 44. Price DB, Russell R, Mares R, et al. Metabolic effects associated with 
ICS in patients with COPD and comorbid type 2 diabetes: a historical 
matched cohort study. PLoS One. 2016;11(9):e0162903.
 45. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of 
diabetes onset and progression. Am J Med. 2010;123(11):1001–1006.
 46. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. 
Inhaled corticosteroids in patients with stable chronic obstructive pul-
monary disease: a systematic review and meta-analysis. JAMA. 2008; 
300(20):2407–2416.
 47. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids 
and the risk of pneumonia in chronic obstructive pulmonary disease: 
a meta-analysis. Arch Intern Med. 2009;169(3):219–229.
 48. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD 
patients receiving inhaled corticosteroids alone or in combination: 
TORCH study results. Eur Respir J. 2009;34(3):641–647.
 49. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone 
propionate and survival in chronic obstructive pulmonary disease. 
N Engl J Med. 2007;356(8):775–789.
 50. Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K. Pneumonia 
among COPD patients using inhaled corticosteroids and long-acting 
bronchodilators. Prim Care Respir J. 2010;19(2):109–117.
 51. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of 
chronic obstructive pulmonary disease exacerbations by salmeterol/
fluticasone propionate or tiotropium bromide. Am J Respir Crit Care 
Med. 2008;177(1):19–26.
 52. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global 
Strategy for Diagnosis, Management, and Prevention of COPD – 
2016. Available from: http://goldcopd.org/global-strategy-diagnosis-
management-prevention-copd-2016/. Accessed July 18, 2017.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
14
 o
n 
18
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2454
Jones et al
Supplementary material
Figure S1 Patient flow diagram.
Abbreviations: COPD, chronic obstructive pulmonary disease; DPI, dry powdered inhaler; FEV1, forced expiratory volume in 1 second; FP/SAL, fluticasone propionate/
salmeterol xinafoate; FVC, forced vital capacity; ICS, inhaled corticosteroids; OPCRD, Optimum Patient Care Research Database; pMDI, pressurized metered-dose inhaler.
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